E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
A Phase 1b Study to Evaluate SIMPONI® (golimumab) Therapy in Children, Adolescents and Young Adults with Pre-Symptomatic Type 1 Diabetes |
|
E.1.1.1 | Medical condition in easily understood language |
Delay of onset or prevention of Type-1 Diabetes |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067584 |
E.1.2 | Term | Type 1 diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to determine the safety and tolerability of golimumab in children, adolescents, and young adults with pre-symptomatic Stage 2 T1D. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to assess the PK and immunogenicity of golimumab in children, adolescents, and young adults with pre-symptomatic Stage 2 T1D. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Is male or female. -Is 6 to 21 years of age, inclusive, with minimal weight of 30 kg. -Is positive for at least 2 of the following diabetes-related autoantibodies obtained at study screening: •Glutamic acid decarboxylase-65 (GADA-65) Autoantibodies •Insulinoma-associated 2 Autoantibodies (IA-2A) •Zinc Transporter-8 (ZnT8) •Islet Cell Cytoplasmic Autoantibodies (ICA) •Insulin Autoantibodies (IAA) Participants with a confirmed documented history of at leas 2 positive diabetes-related autoantibodies but who screen positive on only 1 autoantibody are considered to have met this inclusion criterion 3. -Has a plasma glucose of 7.8 to 11.0 mmol/L (140 to 199 mg/dL) at the 120 minute timepoint of a 2h-OGTT, OR have a plasma glucose of >200 mg/dL (>11.1 mmol/L) at the 30, 60, or 90 minute timepoint of a 2h OGTT OR have a HbA1c ≥5.7% but <6.5% (≥32 to <48 mmol/mol) evaluated at screening. -Is medically stable on the basis of physical examination, medical history, laboratory results, and vital signs performed at screening. Any abnormalities must be consistent with the underlying pre-symptomatic stage of illness in the study population and this determination must be recorded in the participant's source documents and initialed by the investigator.
|
|
E.4 | Principal exclusion criteria |
-Has a current or prior diagnosis of diabetes mellitus (Type 1, Type 2, or gestational) or meet the metabolic criteria diagnostic of diabetes mellitus obtained at screening including: HbA1c ≥6.5% (48 mmol/mol), or Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL) (fasting: no intake ≥8 hours), or Plasma glucose ≥11.1 mmol/L (200 mg/dL) 2 hours post OGTT, or Random plasma glucose ≥11.1 mmol/L (200 mg/dL) in those with symptoms consistent with hyperglycemia crisis. In the absence of unequivocal hyperglycemia, results should be confirmed by repeat testing. -Has a history of moderate or severe progressive or uncontrolled liver or renal insufficiency, significant cardiac (including congestive heart failure), vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or psychiatric disease (such as serious depression, including suicidality). -Has a presence or history of malignancy. -Has a presence or history of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (eg, nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic areas), or clinically significant hepatomegaly or splenomegaly. -Has an immune deficiency syndrome (eg, severe combined immunodeficiency syndrome, T-cell deficiency syndromes, B-cell deficiency syndromes, or chronic granulomatous disease), or bone marrow or organ transplantation, or a disease associated with lymphopenia. -Has other autoimmune diseases (eg, RA, pJIA, PsA, AS, multiple sclerosis, celiac disease, systemic lupus erythematosus) excluding clinically stable autoimmune thyroiditis whether treated or untreated. -Has a concomitant diagnosis or history of demyelinating disease, such as but not limited to multiple sclerosis or Guillain-Barre Syndrome. -Has known or suspected intolerance or hypersensitivity to human proteins, antibody fragments, or monoclonal antibodies, including golimumab or its excipients, or known allergies or severe sensitivity to latex (refer to the golimumab and VarioJect Investigator's Brochures). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety Endpoints -Proportion of participants with treatment-emergent AEs and serious adverse events (SAE) through Week 26 and Week 52. -Proportion of participants with treatment-emergent infections through Week 26 and Week 52. -Proportion of participants with study treatment injection site reactions throughout the study. -Related AE’s and SAE’s reported at the final safety contact point at Week 78. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Safety endpoint assessed at Week 26, 52 and 78. |
|
E.5.2 | Secondary end point(s) |
Pharmacokinetic and Immunogenicity -Summary of serum golimumab concentrations and the PK profile after induction and maintenance dosing. -Incidence and titers of antibodies to golimumab. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Endpoint assessed at week 52. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 9 |